Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma

This study is testing whether adding a drug that blocks a protein called ABCB1 (a pump that can make liver cancer cells resistant to treatment) to a standard procedure called TACE (transarterial chemoembolization) can improve outcomes for patients with liver cancer. TACE delivers chemotherapy directly into the blood vessels feeding the tumor. **You may be eligible if...** - You are 18 or older - You have been diagnosed with hepatocellular carcinoma (the most common type of liver cancer), confirmed by biopsy or imaging - You have at least one tumor that has not been previously treated, measuring between 3 and 8 cm - Your liver function is reasonably preserved (no jaundice, fluid buildup, or confusion from liver failure) **You may NOT be eligible if...** - Your liver function is severely impaired - Your tumor has already been treated or is outside the size range - You have other serious health conditions, including advanced heart or kidney disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.